Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study.

Coulborn RM, Gebrehiwot TG, Schneider M, Gerstl S, Adera C, Herrero M, Porten K, den Boer M, Ritmeijer K, Alvar J, Hassen A, Mulugeta A.

PLoS Negl Trop Dis. 2018 Nov 8;12(11):e0006778. doi: 10.1371/journal.pntd.0006778. eCollection 2018 Nov.

2.

Quantifying the infectiousness of post-kala-azar dermal leishmaniasis towards sandflies.

Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, Nath R, Ghosh P, Chapman L, Alim A, Bilbe G, Alvar J.

Clin Infect Dis. 2018 Oct 24. doi: 10.1093/cid/ciy891. [Epub ahead of print]

PMID:
30357373
3.

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS, Strub-Wourgaft N, Alves F, Rabi Das VN, Topno RK, Sharma B, Balasegaram M, Bern C, Hightower A, Rijal S, Ellis S, Sunyoto T, Burza S, Lima N, Das P, Alvar J.

PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830. doi: 10.1371/journal.pntd.0006830. eCollection 2018 Oct.

4.

Pharmacokinetics, safety and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial.

Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, Alves F.

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy747. [Epub ahead of print]

PMID:
30188978
5.

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, Alvar J.

Clin Microbiol Rev. 2018 Aug 29;31(4). pii: e00048-18. doi: 10.1128/CMR.00048-18. Print 2018 Oct. Review.

PMID:
30158301
6.

Nutritional supplements for patients being treated for active visceral leishmaniasis.

Custodio E, López-Alcalde J, Herrero M, Bouza C, Jimenez C, Storcksdieck Genannt Bonsmann S, Mouratidou T, López-Cuadrado T, Benito A, Alvar J.

Cochrane Database Syst Rev. 2018 Mar 26;3:CD012261. doi: 10.1002/14651858.CD012261.pub2. Review.

PMID:
29578237
7.

Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.

Nieto J, Alvar J, Rodríguez C, San Andrés MI, San Andrés MD, González F.

Res Vet Sci. 2018 Apr;117:125-132. doi: 10.1016/j.rvsc.2017.12.005. Epub 2017 Dec 15.

PMID:
29272720
8.

Cytokines and chemokines measured in dried SLA-stimulated whole blood spots for asymptomatic Leishmania infantum and Leishmania donovani infection.

Ibarra-Meneses AV, Mondal D, Alvar J, Moreno J, Carrillo E.

Sci Rep. 2017 Dec 8;7(1):17266. doi: 10.1038/s41598-017-17315-z.

9.

Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.

Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J.

PLoS Negl Trop Dis. 2017 Nov 16;11(11):e0005877. doi: 10.1371/journal.pntd.0005877. eCollection 2017 Nov. Review.

10.

[GOLD 2017: Proposals and Questions].

Alvar J.

Zhonghua Yi Xue Za Zhi. 2017 Oct 17;97(38):2963-2966. doi: 10.3760/cma.j.issn.0376-2491.2017.38.002. Chinese. No abstract available.

PMID:
29060998
11.

Monocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantum.

Ibarra-Meneses AV, Sanchez C, Alvar J, Moreno J, Carrillo E.

Front Immunol. 2017 Sep 29;8:1208. doi: 10.3389/fimmu.2017.01208. eCollection 2017.

12.

Control of Phlebotomus argentipes (Diptera: Psychodidae) sand fly in Bangladesh: A cluster randomized controlled trial.

Chowdhury R, Faria S, Huda MM, Chowdhury V, Maheswary NP, Mondal D, Akhter S, Akter S, Khan RK, Nabi SG, Kroeger A, Argaw D, Alvar J, Dash AP, Banu Q.

PLoS Negl Trop Dis. 2017 Sep 5;11(9):e0005890. doi: 10.1371/journal.pntd.0005890. eCollection 2017 Sep.

13.

Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.

Bush JT, Wasunna M, Alves F, Alvar J, Olliaro PL, Otieno M, Sibley CH, Strub Wourgaft N, Guerin PJ.

PLoS Negl Trop Dis. 2017 Sep 5;11(9):e0005781. doi: 10.1371/journal.pntd.0005781. eCollection 2017 Sep. Review.

14.

Environmental Factors as Key Determinants for Visceral Leishmaniasis in Solid Organ Transplant Recipients, Madrid, Spain.

Carrasco-Antón N, López-Medrano F, Fernández-Ruiz M, Carrillo E, Moreno J, García-Reyne A, Pérez-Ayala A, Rodríguez-Ferrero ML, Lumbreras C, San-Juan R, Alvar J, Aguado JM.

Emerg Infect Dis. 2017 Jul;23(7):1155-1159. doi: 10.3201/eid2307.151251.

15.

IFN-γ, IL-2, IP-10, and MIG as Biomarkers of Exposure to Leishmania spp., and of Cure in Human Visceral Leishmaniasis.

Ibarra-Meneses AV, Ghosh P, Hossain F, Chowdhury R, Mondal D, Alvar J, Moreno J, Carrillo E.

Front Cell Infect Microbiol. 2017 May 31;7:200. doi: 10.3389/fcimb.2017.00200. eCollection 2017.

16.

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.

Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.

PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635. doi: 10.1371/journal.pntd.0005635. eCollection 2017 May.

17.

Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent.

Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal D, Alvar J.

Clin Infect Dis. 2017 Jul 1;65(1):150-153. doi: 10.1093/cid/cix245.

18.

Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.

Olliaro PL, Shamsuzzaman TA, Marasini B, Dhariwal AC, Be-Nazir A, Mondal D, Banjara MR, Das P, Sundar S, Rijal S, Arana B, Alvar J, Argaw D, Peeling RW, Kroeger A, Matlashewski G.

PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005190. doi: 10.1371/journal.pntd.0005190. eCollection 2017 Jan. No abstract available.

19.

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.

Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.

Clin Drug Investig. 2017 Mar;37(3):259-272. doi: 10.1007/s40261-016-0481-0.

20.

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis.

Wasunna M, Musa A, Hailu A, Khalil EA, Olobo J, Juma R, Wells S, Alvar J, Balasegaram M.

Trans R Soc Trop Med Hyg. 2016 Jun;110(6):321-3. doi: 10.1093/trstmh/trw031. Epub 2016 Jun 7.

21.

Interleukin-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemic.

Ibarra-Meneses AV, Carrillo E, Sánchez C, García-Martínez J, López Lacomba D, San Martin JV, Alves F, Alvar J, Moreno J.

Clin Microbiol Infect. 2016 Aug;22(8):739.e1-4. doi: 10.1016/j.cmi.2016.05.021. Epub 2016 Jun 3.

22.

Cytokine Release Assays as Tests for Exposure to Leishmania, and for Confirming Cure from Leishmaniasis, in Solid Organ Transplant Recipients.

Carrillo E, Carrasco-Antón N, López-Medrano F, Salto E, Fernández L, San Martín JV, Alvar J, Aguado JM, Moreno J.

PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004179. doi: 10.1371/journal.pntd.0004179. eCollection 2015.

23.

Vector and reservoir control for preventing leishmaniasis.

González U, Pinart M, Sinclair D, Firooz A, Enk C, Vélez ID, Esterhuizen TM, Tristan M, Alvar J.

Cochrane Database Syst Rev. 2015 Aug 5;(8):CD008736. doi: 10.1002/14651858.CD008736.pub2. Review.

24.

Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosine.

Kaur H, Seifert K, Hawkes GE, Coumbarides GS, Alvar J, Croft SL.

Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):31-38. doi: 10.4269/ajtmh.14-0586. Epub 2015 Apr 20.

25.

Visceral leishmaniasis and HIV coinfection in the Mediterranean region.

Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3021. doi: 10.1371/journal.pntd.0003021. eCollection 2014 Aug. Review.

26.

How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data.

Chowdhury R, Mondal D, Chowdhury V, Faria S, Alvar J, Nabi SG, Boelaert M, Dash AP.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3020. doi: 10.1371/journal.pntd.0003020. eCollection 2014 Aug.

27.

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.

Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B.

Lancet Glob Health. 2014 Jan;2(1):e51-7. doi: 10.1016/S2214-109X(13)70118-9. Epub 2013 Dec 5.

28.

Visceral leishmaniasis outbreak in South Sudan 2009-2012: epidemiological assessment and impact of a multisectoral response.

Abubakar A, Ruiz-Postigo JA, Pita J, Lado M, Ben-Ismail R, Argaw D, Alvar J.

PLoS Negl Trop Dis. 2014 Mar 27;8(3):e2720. doi: 10.1371/journal.pntd.0002720. eCollection 2014 Mar. No abstract available.

29.

Epidemiology of visceral leishmaniasis in Georgia.

Babuadze G, Alvar J, Argaw D, de Koning HP, Iosava M, Kekelidze M, Tsertsvadze N, Tsereteli D, Chakhunashvili G, Mamatsashvili T, Beria N, Kalandadze I, Ejov M, Imnadze P.

PLoS Negl Trop Dis. 2014 Mar 6;8(3):e2725. doi: 10.1371/journal.pntd.0002725. eCollection 2014 Mar.

30.

Risk factors for visceral Leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia.

Argaw D, Mulugeta A, Herrero M, Nombela N, Teklu T, Tefera T, Belew Z, Alvar J, Bern C.

PLoS Negl Trop Dis. 2013 Nov 7;7(11):e2543. doi: 10.1371/journal.pntd.0002543. eCollection 2013 Nov.

31.

Case study for a vaccine against leishmaniasis.

Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG.

Vaccine. 2013 Apr 18;31 Suppl 2:B244-9. doi: 10.1016/j.vaccine.2012.11.080. Review.

PMID:
23598489
32.

Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.

Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J.

PLoS Negl Trop Dis. 2013;7(3):e2130. doi: 10.1371/journal.pntd.0002130. Epub 2013 Mar 21.

33.

Endemic transmission of visceral leishmaniasis in Bhutan.

Yangzom T, Cruz I, Bern C, Argaw D, den Boer M, Vélez ID, Bhattacharya SK, Molina R, Alvar J.

Am J Trop Med Hyg. 2012 Dec;87(6):1028-37. doi: 10.4269/ajtmh.2012.12-0211. Epub 2012 Oct 22.

34.

Leishmaniasis worldwide and global estimates of its incidence.

Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team.

PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.

35.

Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008).

Gil-Prieto R, Walter S, Alvar J, de Miguel AG.

Am J Trop Med Hyg. 2011 Nov;85(5):820-5. doi: 10.4269/ajtmh.2011.11-0310.

36.

Leishmaniasis impact and treatment access.

den Boer M, Argaw D, Jannin J, Alvar J.

Clin Microbiol Infect. 2011 Oct;17(10):1471-7. doi: 10.1111/j.1469-0691.2011.03635.x. Review.

37.

Visceral leishmaniasis: elimination with existing interventions.

Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J.

Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0. Review.

PMID:
21453873
38.

Multilocus microsatellite typing revealed high genetic variability of Leishmania donovani strains isolated during and after a Kala-azar epidemic in Libo Kemkem district, northwest Ethiopia.

Gelanew T, Cruz I, Kuhls K, Alvar J, Cañavate C, Hailu A, Schönian G.

Microbes Infect. 2011 Jun;13(6):595-601. doi: 10.1016/j.micinf.2011.02.003. Epub 2011 Mar 5.

PMID:
21382503
39.

Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia.

Cañavate C, Herrero M, Nieto J, Cruz I, Chicharro C, Aparicio P, Mulugeta A, Argaw D, Blackstock AJ, Alvar J, Bern C.

Am J Trop Med Hyg. 2011 Jan;84(1):102-6. doi: 10.4269/ajtmh.2011.10-0229.

40.

Population movement: a key factor in the epidemiology of neglected tropical diseases.

Aagaard-Hansen J, Nombela N, Alvar J.

Trop Med Int Health. 2010 Nov;15(11):1281-8. Review.

PMID:
20976871
41.

The leishmaniasis e-compendium: a geo-referenced bibliographic tool.

Hendrickx D, Dujardin JC, Pickering J, Alvar J.

Trends Parasitol. 2010 Nov;26(11):515-6. doi: 10.1016/j.pt.2010.06.015. Epub 2010 Jul 14. No abstract available.

PMID:
20634139
42.

Designing and reporting clinical trials on treatments for cutaneous leishmaniasis.

González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J.

Clin Infect Dis. 2010 Aug 15;51(4):409-19. doi: 10.1086/655134. Review.

PMID:
20624067
43.

Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

Valdivieso E, Rangel A, Moreno J, Saugar JM, Cañavate C, Alvar J, Dagger F.

Exp Parasitol. 2010 Dec;126(4):557-63. doi: 10.1016/j.exppara.2010.06.002. Epub 2010 Jun 8.

PMID:
20566367
44.

Combination therapy for visceral leishmaniasis.

van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M.

Lancet Infect Dis. 2010 Mar;10(3):184-94. doi: 10.1016/S1473-3099(10)70011-6. Review.

PMID:
20185097
45.

Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination.

Bern C, Courtenay O, Alvar J.

PLoS Negl Trop Dis. 2010 Feb 9;4(2):e599. doi: 10.1371/journal.pntd.0000599. Review. Erratum in: PLoS Negl Trop Dis. 2010;4(3). doi: 10.1371/annotation/f96dd2ce-05de-4aa5-a9d5-c481b0745c84.

46.

Developments in the treatment of visceral leishmaniasis.

den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M.

Expert Opin Emerg Drugs. 2009 Sep;14(3):395-410. doi: 10.1517/14728210903153862. Review.

PMID:
19708817
47.

Natural history of a visceral leishmaniasis outbreak in highland Ethiopia.

Herrero M, Orfanos G, Argaw D, Mulugeta A, Aparicio P, Parreño F, Bernal O, Rubens D, Pedraza J, Lima MA, Flevaud L, Palma PP, Bashaye S, Alvar J, Bern C.

Am J Trop Med Hyg. 2009 Sep;81(3):373-7.

PMID:
19706898
48.

Risk factors for visceral leishmaniasis in a new epidemic site in Amhara Region, Ethiopia.

Bashaye S, Nombela N, Argaw D, Mulugeta A, Herrero M, Nieto J, Chicharro C, Cañavate C, Aparicio P, Vélez ID, Alvar J, Bern C.

Am J Trop Med Hyg. 2009 Jul;81(1):34-9.

PMID:
19556563
49.

Interventions for American cutaneous and mucocutaneous leishmaniasis.

González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004834. doi: 10.1002/14651858.CD004834.pub2. Review.

PMID:
19370612
50.

Complexities of assessing the disease burden attributable to leishmaniasis.

Bern C, Maguire JH, Alvar J.

PLoS Negl Trop Dis. 2008;2(10):e313. doi: 10.1371/journal.pntd.0000313. Epub 2008 Oct 29. Review.

Supplemental Content

Support Center